TG Therapeutics Inc. stocks have been trading up by 8.99 percent after positive sentiment around its latest clinical trial progress.
Click Here for a Millionaire's POV on Trading TGTX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Phase 3 ENHANCE trial showed Briumvi’s new single 600 mg Day 1 infusion is bioequivalent to the current two‑step regimen, with a supplemental BLA planned in 2H 2026.
- Positive Phase 1 subcutaneous Briumvi data in multiple sclerosis support a high‑concentration, low‑volume at‑home option and advancement into Phase 3.
- A pooled ULTIMATE I & II analysis found Briumvi outperformed teriflunomide on clinical and MRI outcomes in treatment‑naive relapsing MS, including early‑stage patients.
- Subcutaneous Briumvi in myasthenia gravis showed rapid MG‑ADL improvements and triggered a Phase 2 maintenance trial after efgartigimod induction.
- TGTX shares spiked roughly 10–11% on the subcutaneous MS data, underscoring strong trader focus on convenience‑driven Briumvi formulations.
Live Update At 12:32:18 EDT: On Wednesday, June 10, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 8.99%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TGTX is trading like a biotech name with real fundamentals finally catching up to the chart. Over the past few weeks, TG Therapeutics stock has climbed from closes around $37–$40 into the high $40s, with the most recent daily close at $47.27 after a push as high as $49.305. That is a sharp trend higher, and traders should recognize it as momentum backed by news, not just hype.
Intraday action shows TGTX holding gains rather than giving them back. After the morning spike from a $43.37 open to above $49, the 5‑minute candles mostly chopped between $47 and $48.8. That tells traders dip‑buyers kept stepping in, a classic strength signal.
On the fundamentals, TG Therapeutics printed $204.9M in quarterly revenue and $19.8M in net income, with a fat 92.6% gross margin. A price‑to‑sales ratio around 7.7 and a P/E near 11.8 are not cheap for a typical stock, but for a commercial‑stage biotech with 333% three‑year revenue growth, traders often pay up.
More Breaking News
- Robinhood HOOD Stock Rallies As Wall Street Hikes Targets
- SJM Stock Climbs As Wall Street Warms Ahead Of Earnings
- MARA Stock Slips As Analysts Slash Price Targets After Q1 Miss
- DOGZ Stock Sees Volatile Spike As Traders Hunt Momentum
The balance sheet is also important. TGTX holds $442.2M in cash and short‑term liquidity, with a strong current ratio of 5.8 and working capital near $900M. Debt is not trivial, but interest coverage around 4.9 and very high recent returns on capital suggest management is using leverage to scale Briumvi, not just plug holes. For active traders, that combination of rapid top‑line growth, profitability, and strong liquidity is fuel for sustained trend moves as long as the clinical news keeps landing.
Why Traders Are Watching TGTX Right Now
TGTX is on a clinical news tear, and the market is noticing. For active traders, this is exactly the type of story that can trend for months when the data line up with the chart.
The biggest de‑risking event is the Phase 3 ENHANCE trial. TG Therapeutics showed that a single 600 mg Day 1 Briumvi infusion in relapsing multiple sclerosis is bioequivalent to the current Day 1/Day 15 split start, with comparable safety and MRI outcomes and no new safety signals. That matters because simpler dosing usually means easier adoption. If neurologists can start patients with one infusion instead of two, Briumvi becomes more convenient in practice without giving up efficacy, and TGTX plans a supplemental BLA filing in 2H 2026.
Layered on top is the high‑concentration subcutaneous formulation of Briumvi. Early Phase 1 data show more than 60% bioavailability versus IV, strong pharmacokinetic and pharmacodynamic alignment, and clean safety. Modeling suggests quarterly or every‑other‑month at‑home dosing should hit non‑inferiority exposure targets in a fully enrolled Phase 3 trial, with key readouts coming in late 2026 or early 2027 and potential approval around 2028. Management is openly talking about nearly doubling Briumvi’s addressable market with a self‑administered anti‑CD20.
Add the ULTIMATE I & II pooled analysis, where Briumvi beat teriflunomide on clinical and MRI outcomes in treatment‑naive relapsing MS, especially in early disease. That gives TG Therapeutics marketing ammo against an entrenched competitor and supports a push into first‑line use. For TGTX traders, this is the core of the bull case: better drug profile, easier dosing, and a long runway of catalysts.
On top of MS, the subcutaneous Briumvi data in myasthenia gravis show strong and rapid MG‑ADL improvements with a safety profile consistent with IV use in MS. TG Therapeutics already launched a Phase 2 trial testing Briumvi as maintenance after efgartigimod induction. That is not near‑term revenue, but it widens the franchise, giving TGTX optionality beyond MS.
The stock’s reaction tells you how central this story has become. TGTX jumped 10–11% on the first subcutaneous MS data, more than 5% premarket on follow‑up details, and roughly 10.6% intraday to about $40.53 during the main run. When a name rallies this hard on clinical convenience and maintains those gains on the tape, momentum traders pay attention.
Conclusion
For active traders who thrive on volatility plus real catalysts, TGTX is checking a lot of boxes right now. TG Therapeutics has a commercial product in Briumvi, expanding data that show it can out‑perform teriflunomide in relapsing MS, and a clear push toward simpler IV dosing via the ENHANCE trial. At the same time, subcutaneous Briumvi in MS and myasthenia gravis gives the TGTX pipeline a second leg: convenience and new indications.
Financially, this is not a pre‑revenue gamble. TG Therapeutics is posting over $200M in quarterly revenue, positive net income, and extremely high gross margins, backed by a strong liquidity position. That reduces one of the biggest risks that normally scares traders away from biotech: constant dilution. With cash in the bank and access to debt already tapped, TGTX can focus on executing its clinical plan rather than racing back to the market for funding every few months.
Still, none of this guarantees a straight line higher. The market has already rewarded TGTX for the Phase 1 and Phase 3 wins; the bar for future data is now higher. Any stumble in the Phase 3 subcutaneous program or delays in the supplemental BLA could trigger sharp pullbacks. That is where discipline matters.
As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your plan.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.”. For traders studying TGTX, that means tracking the calendar of Briumvi catalysts, respecting the volatility, and always having a clear entry, risk level, and exit before pressing the buy button. This article is for educational and research purposes only and is not trading advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.